Compare Gold Fields Limited (GFI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs ResMed Inc. — how do they compare? Gold Fields Limited trades at $40.78 (market cap $36.07B), while ResMed Inc. trades at $225.56 (market cap $32.61B). The key difference: Gold Fields Limited and ResMed Inc. are close in size by market cap, and Gold Fields Limited pays the higher dividend (5.76%). Which is the better fit depends on your goals.
| GFI | RMD | |
|---|---|---|
Market Cap | $36.07B | $32.61B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $293.73 |
52-Week Low | $29.31 | $182.82 |
Enterprise Value | $37.51B | $31.97B |
Dividend Yield | 5.76% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $41.06, down 0.16% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows strong fundamentals with a P/E of 10.22, net income margin of 40.76%, and robust cash flow growth, with 2025 projections indicating revenue of $8.8B and net income of $3.6B. Recent news highlights institutional buying interest, such as Assenagon Asset Management's new position in Q2 2026.
The outlook for GFI is positive, supported by high profitability and growth projections, though risks include volatile gold prices and cost pressures. Analyst consensus is a Buy with a $52 price target, suggesting 27% upside. Investors should weigh strong cash generation against debt increases and market sentiment shifts.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
